CR Bard's CEO Discusses Q1 2012 Results - Earnings Call Transcript

CR Bard (BCR)

Q1 2012 Earnings Call

April 24, 2012 5:00 pm ET


Timothy M. Ring - Chairman, Chief Executive Officer and Chairman of Executive Committee

John H. Weiland - President, Chief Operating Officer and Director

Todd C. Schermerhorn - Chief Financial Officer and Senior Vice President

John A. DeFord - Senior Vice President of Science Technology & Clinical Affairs


Jonathan J. Palmer - Credit Agricole Securities (USA) Inc., Research Division

Michael Matson - Mizuho Securities USA Inc., Research Division

Michael N. Weinstein - JP Morgan Chase & Co, Research Division

Frederick A. Wise - Leerink Swann LLC, Research Division

Matthew J. Dodds - Citigroup Inc, Research Division

Jason Wittes - Caris & Company, Inc., Research Division

David R. Lewis - Morgan Stanley, Research Division

Topher Orr - Goldman Sachs Group Inc., Research Division

Kristen M. Stewart - Deutsche Bank AG, Research Division

Matthew O'Brien - William Blair & Company L.L.C., Research Division

Lennox Ketner - BofA Merrill Lynch, Research Division

Daniel Sollof - Barclays Capital, Research Division

Joshua T. Jennings - Cowen and Company, LLC, Research Division

Anthony Petrone - Jefferies & Company, Inc., Research Division

Robert M. Goldman - CL King & Associates, Inc.



Ladies and gentlemen, thank you for standing by. Welcome to the C. R. Bard, Inc. First Quarter 2012 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand replay through Bard's website. Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with Jay H. Weiland, President and Chief Operating Officer; Todd C. Schermerhorn, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations.

Today, Bard's management will discuss some forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties. Please refer to the cautionary statement regarding forward-looking information and the information under the caption Risk Factors, each in Bard's 2011 10-K, including disclosures of factors that could cause actual results to differ materially from those expressed or implied.

If you liked this article you might like

EY's Greene Sees More Med Tech, CRO Deals Ahead

Deals of the Week: Waiting for Clarity

Merger Buzz Drives Akorn to Top of Health Chart in April

Deals of the Week: Reason for Optimism

Good Medicine Makes for 3 Good Charts